Denise A Lopez Domowicz1, Ian Welsby2, Charles R Esther3, Hongmei Zhu4, Robert D Marek4, Grace Lee4, Nirmish Shah1,4, Jessica L Poisson5, Tim J McMahon4,6. 1. Department of Pediatrics, Duke University Medical Center, Durham, NC, United States of America. 2. Department of Anesthesiology, Duke University Medical Center, Durham, NC, United States of America. 3. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America. 4. Department of Medicine, Duke University Medical Center, Durham, NC, United States of America. 5. Department of Pathology, Duke University Medical Center, Durham, NC, United States of America. 6. Durham Vetern Affairs Health Care System, Durham, NC, United States of America.
Abstract
BACKGROUND:Red blood cell (RBC) exchange (RCE) transfusion therapy is indicated for certain patients with sickle cell disease (SCD). Although beneficial, this therapy is costly and inconvenient to patients, who may require it monthly or more often. Identification of blood and plasma biomarkers that could improve or help individualise RCE therapy is of interest. Here we examined relevant blood and plasma metabolites and biomarkers of vasoactivity and RBC fragility in a pilot study of SCD patients undergoing RCE using either standard RBC units or RBC units treated with aUS Food and Drug Administration (FDA)-approved additive solution containing phosphate, inosine, pyruvate, and adenine ("PIPA"). MATERIALS AND METHODS: In this prospective, single-blind, cross-over pilot clinical trial, patients were randomised to receive either standard RBC exchange or PIPA-treated RBC exchange transfusion with each RCE session over a 6-month treatment period. Pre- and post-transfusion blood samples were obtained and analysed for RBC O2 affinity, ATP, purine metabolites, RBC microparticles, and cell free haemoglobin. RESULTS:Red blood cell O2 affinity was maintained after PIPA-RCE in contrast to standard RCE, after which P50 fell (net O2 affinity rose). Plasma ATP did not change significantly after RCE using either of the RBC unit types. Exchange transfusion with PIPA-treated RBC units led to modest increases in plasma inosine and hypoxanthine. Plasma cell free haemoglobin fell after either standard or PIPA-treated RBC exchange transfusion (novel findings), and to a similar extent. RBC-derived microparticles in the plasma fell significantly and similarly after both standard and PIPA-treated RCE transfusion. DISCUSSION: In summary, treatment of RBCs with PIPA prior to RCE elicited favourable or neutral changes in key metabolic and vascular biomarkers. Further study of its efficacy and safety is recommended and could ultimately serve to improve outcomes in chronically transfused SCD patients.
RCT Entities:
BACKGROUND: Red blood cell (RBC) exchange (RCE) transfusion therapy is indicated for certain patients with sickle cell disease (SCD). Although beneficial, this therapy is costly and inconvenient to patients, who may require it monthly or more often. Identification of blood and plasma biomarkers that could improve or help individualise RCE therapy is of interest. Here we examined relevant blood and plasma metabolites and biomarkers of vasoactivity and RBC fragility in a pilot study of SCDpatients undergoing RCE using either standard RBC units or RBC units treated with a US Food and Drug Administration (FDA)-approved additive solution containing phosphate, inosine, pyruvate, and adenine ("PIPA"). MATERIALS AND METHODS: In this prospective, single-blind, cross-over pilot clinical trial, patients were randomised to receive either standard RBC exchange or PIPA-treated RBC exchange transfusion with each RCE session over a 6-month treatment period. Pre- and post-transfusion blood samples were obtained and analysed for RBC O2 affinity, ATP, purine metabolites, RBC microparticles, and cell free haemoglobin. RESULTS: Red blood cell O2 affinity was maintained after PIPA-RCE in contrast to standard RCE, after which P50 fell (net O2 affinity rose). Plasma ATP did not change significantly after RCE using either of the RBC unit types. Exchange transfusion with PIPA-treated RBC units led to modest increases in plasma inosine and hypoxanthine. Plasma cell free haemoglobin fell after either standard or PIPA-treated RBC exchange transfusion (novel findings), and to a similar extent. RBC-derived microparticles in the plasma fell significantly and similarly after both standard and PIPA-treated RCE transfusion. DISCUSSION: In summary, treatment of RBCs with PIPA prior to RCE elicited favourable or neutral changes in key metabolic and vascular biomarkers. Further study of its efficacy and safety is recommended and could ultimately serve to improve outcomes in chronically transfused SCDpatients.
Authors: J S Raval; J H Waters; A Seltsam; E A Scharberg; E Richter; A R Daly; M V Kameneva; M H Yazer Journal: Vox Sang Date: 2010-11 Impact factor: 2.144
Authors: Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia Journal: Nat Med Date: 2010-12-19 Impact factor: 53.440
Authors: Eldad A Hod; Gary M Brittenham; Genia B Billote; Richard O Francis; Yelena Z Ginzburg; Jeanne E Hendrickson; Jeffrey Jhang; Joseph Schwartz; Shruti Sharma; Sujit Sheth; Anthony N Sireci; Hannah L Stephens; Brie A Stotler; Boguslaw S Wojczyk; James C Zimring; Steven L Spitalnik Journal: Blood Date: 2011-10-20 Impact factor: 22.113
Authors: Nicolaas J H Raat; Petra M Hilarius; Tanja Johannes; Dirk de Korte; Can Ince; Arthur J Verhoeven Journal: Transfusion Date: 2008-11-25 Impact factor: 3.157